Literature DB >> 8699083

Immune response to recombinant mycobacterial proteins in patients with tuberculosis infection and disease.

V Mehra1, J H Gong, D Iyer, Y Lin, C T Boylen, B R Bloom, P F Barnes.   

Abstract

The capacity of four Mycobacterium tuberculosis recombinant antigens to elicit proliferation and cytokine production by human T cells was evaluated. Proliferative responses of peripheral blood mononuclear cells (PBMC) to all antigens were greater in healthy tuberculin reactors than in pulmonary tuberculosis patients, and proliferative responses of pleural fluid cells were greater than those of PBMC from patients with tuberculous pleuritis. The proliferative responses to the four recombinant antigens were similar in all patient groups, and there was no selective unresponsiveness to any antigen in pulmonary tuberculosis patients. The 38-kDa antigen induced less interferon-gamma than did the 10-, 30-, and 65-kDa antigens, and all four antigens induced similar amounts of interleukin-10. These results suggest that none of the four recombinant antigens are immunodominant, and that the 10-, 30-, and 65-kDa antigens are similar in their capacity to induce a potentially protective Th1-like response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699083     DOI: 10.1093/infdis/174.2.431

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  In situ activation of helper T cells in the lung.

Authors:  B Raju; C F Tung; D Cheng; N Yousefzadeh; R Condos; W N Rom; D B Tse
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  In vitro levels of interleukin 10 (IL-10) and IL-12 in response to a recombinant 32-kilodalton antigen of Mycobacterium bovis BCG after treatment for tuberculosis.

Authors:  V Hari Sai Priya; B Anuradha; Suman Latha Gaddam; Seyed E Hasnain; K J R Murthy; Vijaya Lakshmi Valluri
Journal:  Clin Vaccine Immunol       Date:  2008-11-05

Review 3.  Genetic vaccination against tuberculosis.

Authors:  D B Lowrie; C L Silva; R E Tascon
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Kinetics of purified protein derivative (PPD) proliferation reflects underlying suppressor mechanisms revealed by limiting dilution analysis (LDA) in patients with extrapulmonary tuberculosis (TB).

Authors:  P T Lukey; S E Latouf; S R Ress
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

5.  Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis.

Authors:  A D Lein; C F von Reyn; P Ravn; C R Horsburgh; L N Alexander; P Andersen
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

6.  CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals.

Authors:  Matthew W Auten; Weitao Huang; Guixiang Dai; Alistair J Ramsay
Journal:  Vaccine       Date:  2012-02-18       Impact factor: 3.641

7.  Differential T-cell recognition of native and recombinant Mycobacterium tuberculosis GroES.

Authors:  I Rosenkrands; K Weldingh; P Ravn; L Brandt; P Højrup; P B Rasmussen; A R Coates; M Singh; P Mascagni; P Andersen
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 8.  Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.

Authors:  C Sander; H McShane
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

9.  Naive human T cells develop into Th1 effectors after stimulation with Mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins.

Authors:  D M Russo; N Kozlova; D L Lakey; D Kernodle
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

10.  Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens.

Authors:  R L Skjøt; T Oettinger; I Rosenkrands; P Ravn; I Brock; S Jacobsen; P Andersen
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.